New and emerging HDAC inhibitors for cancer treatment

Discovery of adamantane based highly potent HDAC inhibitors

(2013) Balasubramanian Gopalan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function

(2013) M. R. Heideman et al.   BLOOD

A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance

(2013) F. Santoro et al.   BLOOD

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors

(2013) M New et al.   CELL DEATH AND DIFFERENTIATION

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials

(2013) Tianzhu Qiu et al.   Future Oncology

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

(2013) Mercedes Lobera et al.   Nature Chemical Biology

HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

(2013) J E Bolden et al.   Cell Death & Disease

Expansion of the Lysine Acylation Landscape

(2012) Christian A. Olsen   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

(2012) Mei Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

(2012) U. Banerji et al.   CLINICAL CANCER RESEARCH

HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

(2012) K.-T. Lin et al.   CLINICAL CANCER RESEARCH

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

(2012) Madeleine Duvic et al.   EUROPEAN JOURNAL OF CANCER

Targeting class I histone deacetylases in cancer therapy

(2012) Geneviève P Delcuve et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed

(2012) Berkley E Gryder et al.   Future Medicinal Chemistry

HDAC11 is a novel drug target in carcinomas

(2012) Hedwig E. Deubzer et al.   INTERNATIONAL JOURNAL OF CANCER

HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins

(2012) Kwang Hwa Jung et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia

(2012) Elisabetta Soragni et al.   JOURNAL OF CHILD NEUROLOGY

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovering the Binding Modes of Natural Products with Histone Deacetylase 1

(2012) Lei Zhang et al.   Medicinal Chemistry

HDAC inhibitor-based therapies: Can we interpret the code?

(2012) Maria New et al.   Molecular Oncology

Trials with ‘epigenetic’ drugs: An update

(2012) Angela Nebbioso et al.   Molecular Oncology

HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle

(2012) Matthew A. Deardorff et al.   NATURE

Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages

(2012) X. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

(2011) W. P. Yong et al.   ANNALS OF ONCOLOGY

Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis

(2011) Jelena Vojinovic et al.   ARTHRITIS AND RHEUMATISM

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

(2011) A R A Razak et al.   BRITISH JOURNAL OF CANCER

Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification

(2011) Minjia Tan et al.   CELL

Histone Deacetylases 9 and 10 Are Required for Homologous Recombination

(2011) Shweta Kotian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

(2011) Anas Younes et al.   LANCET ONCOLOGY

Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung

(2011) Yoshihiro Minamiya et al.   LUNG CANCER

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

(2011) Chiranjeevi Sandi et al.   NEUROBIOLOGY OF DISEASE

Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas

(2011) B. S. Taylor et al.   Cancer Discovery

Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides

(2010) Jerome C. Bressi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

(2010) Daniel Antunes Moreno et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability

(2010) Srividya Bhaskara et al.   CANCER CELL

HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth

(2010) T. Milde et al.   CLINICAL CANCER RESEARCH

Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis

(2010) Roel H Wilting et al.   EMBO JOURNAL

Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma

(2010) Heiner Adams et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression

(2010) T. Yamaguchi et al.   GENES & DEVELOPMENT

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

(2009) L. Ellis et al.   BLOOD

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

A phosphorylation-acetylation switch regulates STAT1 signaling

(2009) O. H. Kramer et al.   GENES & DEVELOPMENT

HDAC4 Represses Vascular Endothelial Growth Factor Expression in Chondrosarcoma by Modulating RUNX2 Activity

(2009) Xiaojuan Sun et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

(2009) Axel Hauschild et al.   MELANOMA RESEARCH

Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM

(2009) S. Malik et al.   MOLECULAR AND CELLULAR BIOLOGY

Genetic dissection of histone deacetylase requirement in tumor cells

(2009) M. Haberland et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

(2008) Jung-Hyun Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

(2008) W Weichert et al.   BRITISH JOURNAL OF CANCER

Histone deacetylase inhibitors and genomic instability

(2008) Grégory Eot-Houllier et al.   CANCER LETTERS

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

(2008) C. Bonfils et al.   CLINICAL CANCER RESEARCH

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

(2008) W. Weichert et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

(2008) I. Oehme et al.   CLINICAL CANCER RESEARCH

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

(2008) Stephanie Spange et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity

(2008) Anja Schuetz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

(2008) Wilko Weichert et al.   LANCET ONCOLOGY

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

(2008) S Balasubramanian et al.   LEUKEMIA

HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21

(2008) Andrew J. Wilson et al.   MOLECULAR BIOLOGY OF THE CELL

Destabilization of ERBB2 Transcripts by Targeting 3' Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6

(2008) G. K. Scott et al.   MOLECULAR CANCER RESEARCH

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

(2008) A. Newbold et al.   MOLECULAR CANCER THERAPEUTICS

HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism

(2008) D Mottet et al.   ONCOGENE